XML 22 R13.htm IDEA: XBRL DOCUMENT
v3.23.1

Segment Data | 6 Months Ended
--- | ---
Mar. 31, 2023
Segment Reporting [Abstract] |
Segment Data | Segment Data The Company's organizational structure is based upon three worldwide business segments: BD Medical (“Medical”), BD Life Sciences (“Life Sciences”) and BD Interventional (“Interventional”). The Company's segments are strategic businesses that are managed separately because each one develops, manufactures and markets distinct products and services. Segment disclosures are on a performance basis consistent with internal management reporting. The Company evaluates performance of its business segments and allocates resources to them primarily based upon segment operating income, which represents revenues reduced by product costs and operating expenses. Prior to its spin-off on April 1, 2022, the Company reported the Diabetes Care business as an organizational unit within the Medical segment. As such, historical financial information of the Medical segment has been recast in the tables below to reflect the total segment revenues and revenues from continuing operations. Revenues and operating income from the Diabetes Care business prior to its spin-off are included in Income from Discontinued Operations, Net of Tax. See Note 2 for further information. Revenues by segment, organizational unit and geographical areas for the three and six-month periods are detailed below. The Company has no material intersegment revenues.
| Three Months Ended March 31,
(Millions of dollars) | 2023 |  | 2022
| United States |  | International |  | Total |  | United States |  | International |  | Total
Medical |  |  |  |  |  |  |  |  |  |  |
Medication Delivery Solutions (a) | $ | 616 |  |  | $ | 454 |  |  | $ | 1,070 |  |  | $ | 590 |  |  | $ | 460 |  |  | $ | 1,049 |
Medication Management Solutions | 550 |  |  | 173 |  |  | 723 |  |  | 461 |  |  | 143 |  |  | 604 |
Pharmaceutical Systems (a) | 173 |  |  | 394 |  |  | 567 |  |  | 125 |  |  | 375 |  |  | 501 |
Total segment revenues | $ | 1,339 |  |  | $ | 1,022 |  |  | $ | 2,360 |  |  | $ | 1,176 |  |  | $ | 978 |  |  | $ | 2,154 |
Life Sciences |  |  |  |  |  |  |  |  |  |  |
Integrated Diagnostic Solutions | $ | 422 |  |  | $ | 466 |  |  | $ | 888 |  |  | $ | 618 |  |  | $ | 532 |  |  | $ | 1,150 |
Biosciences | 159 |  |  | 228 |  |  | 386 |  |  | 129 |  |  | 206 |  |  | 335 |
Total segment revenues | $ | 581 |  |  | $ | 694 |  |  | $ | 1,275 |  |  | $ | 747 |  |  | $ | 738 |  |  | $ | 1,485 |
Interventional |  |  |  |  |  |  |  |  |  |  |
Surgery | $ | 295 |  |  | $ | 86 |  |  | $ | 381 |  |  | $ | 268 |  |  | $ | 72 |  |  | $ | 340 |
Peripheral Intervention | 256 |  |  | 213 |  |  | 468 |  |  | 240 |  |  | 210 |  |  | 450 |
Urology and Critical Care | 263 |  |  | 74 |  |  | 336 |  |  | 239 |  |  | 82 |  |  | 320 |
Total segment revenues | $ | 813 |  |  | $ | 373 |  |  | $ | 1,186 |  |  | $ | 746 |  |  | $ | 364 |  |  | $ | 1,111 |
Total revenues from continuing operations | $ | 2,733 |  |  | $ | 2,088 |  |  | $ | 4,821 |  |  | $ | 2,669 |  |  | $ | 2,081 |  |  | $ | 4,750 |
(a)Certain prior-period amounts were recast to reflect former intercompany transactions with Embecta.
| Six Months Ended March 31,
(Millions of dollars) | 2023 |  | 2022
| United States |  | International |  | Total |  | United States |  | International |  | Total
Medical |  |  |  |  |  |  |  |  |  |  |
Medication Delivery Solutions (a) | $ | 1,235 |  |  | $ | 873 |  |  | $ | 2,109 |  |  | $ | 1,210 |  |  | $ | 936 |  |  | $ | 2,146 |
Medication Management Solutions | 1,114 |  |  | 316 |  |  | 1,430 |  |  | 945 |  |  | 286 |  |  | 1,231 |
Pharmaceutical Systems (a) | 292 |  |  | 684 |  |  | 976 |  |  | 228 |  |  | 669 |  |  | 897 |
Total segment revenues | $ | 2,642 |  |  | $ | 1,873 |  |  | $ | 4,515 |  |  | $ | 2,383 |  |  | $ | 1,892 |  |  | $ | 4,274 |
Life Sciences |  |  |  |  |  |  |  |  |  |  |
Integrated Diagnostic Solutions | $ | 930 |  |  | $ | 911 |  |  | $ | 1,841 |  |  | $ | 1,232 |  |  | $ | 1,062 |  |  | $ | 2,295 |
Biosciences | 296 |  |  | 440 |  |  | 736 |  |  | 258 |  |  | 416 |  |  | 674 |
Total segment revenues | $ | 1,226 |  |  | $ | 1,351 |  |  | $ | 2,577 |  |  | $ | 1,490 |  |  | $ | 1,478 |  |  | $ | 2,968 |
Interventional |  |  |  |  |  |  |  |  |  |  |
Surgery | $ | 582 |  |  | $ | 162 |  |  | $ | 744 |  |  | $ | 549 |  |  | $ | 152 |  |  | $ | 701 |
Peripheral Intervention | 492 |  |  | 410 |  |  | 902 |  |  | 457 |  |  | 407 |  |  | 863 |
Urology and Critical Care | 522 |  |  | 148 |  |  | 670 |  |  | 492 |  |  | 168 |  |  | 661 |
Total segment revenues | $ | 1,595 |  |  | $ | 720 |  |  | $ | 2,315 |  |  | $ | 1,498 |  |  | $ | 727 |  |  | $ | 2,225 |
Total Company revenues from continuing operations | $ | 5,462 |  |  | $ | 3,944 |  |  | $ | 9,407 |  |  | $ | 5,372 |  |  | $ | 4,096 |  |  | $ | 9,468 |
(a)Certain prior-period amounts were recast to reflect former intercompany transactions with Embecta. Segment income for the three and six-month periods was as follows:
| Three Months Ended March 31, |  | Six Months Ended March 31,
(Millions of dollars) | 2023 |  | 2022 |  | 2023 |  | 2022
Income from Continuing Operations Before Income Taxes |  |  |  |  |  |  |
Medical (a) | $ | 641 |  |  | $ | 476 |  |  | $ | 1,195 |  |  | $ | 1,048 |
Life Sciences | 394 |  |  | 475 |  |  | 827 |  |  | 1,009 |
Interventional | 297 |  |  | 280 |  |  | 598 |  |  | 544 |
Total Segment Operating Income | 1,333 |  |  | 1,231 |  |  | 2,621 |  |  | 2,602 |
Acquisition-related integration and restructuring expense | (62) |  |  | (28) |  |  | (106) |  |  | (62) |
Net interest expense | (108) |  |  | (95) |  |  | (204) |  |  | (191) |
Other unallocated items (b) | (635) |  |  | (665) |  |  | (1,301) |  |  | (1,307) |
Total Income from Continuing Operations Before Income Taxes | $ | 529 |  |  | $ | 442 |  |  | $ | 1,009 |  |  | $ | 1,041 |
(a)The amounts for the three and six months ended March 31, 2022 include a charge of $54 million recorded to Cost of products sold to write down the carrying value of certain fixed assets in the Pharmaceutical Systems unit, as well as a charge of $35 million to adjust estimated future product remediation costs. (b)Primarily comprised of foreign exchange, certain general and administrative expenses and share-based compensation expense.

X
- References No definition available. + Details
Name: | us-gaap_SegmentReportingAbstract
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition The entire disclosure for reporting segments including data and tables. Reportable segments include those that meet any of the following quantitative thresholds a) it's reported revenue, including sales to external customers and intersegment sales or transfers is 10 percent or more of the combined revenue, internal and external, of all operating segments b) the absolute amount of its reported profit or loss is 10 percent or more of the greater, in absolute amount of 1) the combined reported profit of all operating segments that did not report a loss or 2) the combined reported loss of all operating segments that did report a loss c) its assets are 10 percent or more of the combined assets of all operating segments. + References Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 31 -URI https://asc.fasb.org/extlink&oid=126901519&loc=d3e8924-108599 Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 34 -URI https://asc.fasb.org/extlink&oid=126901519&loc=d3e8981-108599 Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 21 -Subparagraph (a) -URI https://asc.fasb.org/extlink&oid=126901519&loc=d3e8721-108599 Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 40 -URI https://asc.fasb.org/extlink&oid=126901519&loc=d3e9031-108599 Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 32 -Subparagraph (f) -URI https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599 Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 32 -Subparagraph (e) -URI https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599 Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 26 -URI https://asc.fasb.org/extlink&oid=126901519&loc=d3e8844-108599 Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 41 -URI https://asc.fasb.org/extlink&oid=126901519&loc=d3e9038-108599 Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 32 -Subparagraph (d) -URI https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599 Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 22 -URI https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599 Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 42 -URI https://asc.fasb.org/extlink&oid=126901519&loc=d3e9054-108599 Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 15 -URI https://asc.fasb.org/extlink&oid=126901519&loc=d3e8657-108599 Reference 13: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 21 -Subparagraph (b) -URI https://asc.fasb.org/extlink&oid=126901519&loc=d3e8721-108599 Reference 14: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -URI https://asc.fasb.org/topic&trid=2134510 + Details
Name: | us-gaap_SegmentReportingDisclosureTextBlock
Namespace Prefix: | us-gaap_
Data Type: | dtr-types:textBlockItemType
Balance Type: | na
Period Type: | duration